Feature | November 08, 2013

Approval Of Boston Scientific's Watchman Device Will Support Rapid Growth in LAA Closure Device Market

LAA occluder, Watchman

Boston Scientific's Watchman LAA occluder device is designed to prevent stroke in patients atrial fibrillation without the need for warfarin therapy.

November 8, 2013 – According to Millennium Research Group (MRG), the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's Watchman device will drive rapid growth in the market for global left arterial appendage (LAA) closure devices.

Although a number of epicardial LAA closure devices are available worldwide, the Watchman device will represent the first FDA-approved endocardial LAA device when it enters the market in the latter half of 2013. Approval is more difficult to obtain for endocardial devices because they are placed directly inside the LAA opening of the heart, whereas epicardial devices function from outside of the heart.

"Endocardial LAA closure devices have huge global market potential," said MRG Senior Analyst Sean Messenger. "These devices will expand the eligible patient pool for LAA closure because they will be approved for stand-alone use in the US, as they are in Europe. By contrast, the majority of epicardial devices are only approved for concomitant use when patients are undergoing open cardiac surgery for another condition. Physicians are also familiar with endocardial devices given that interventional cardiologists have been using very similar devices for many years."

Market growth will be particularly strong in the United States, where clinical trial results from the PROTECT-AF and PREVAIL studies will support device approval and encourage physician adoption of the Watchman device. FDA approval is also highly regarded in Europe, and as a result, the Watchman device will see strong uptake in this market as well. The device will not enter the Japanese market until it has been well-established in the United States and Europe, although market growth is expected to be strong once endocardial LAA devices enter this space.

St. Jude Medical, the current global leader of the heart defect closure device market, is also expected to eventually enter the endocardial LAA closure device segment; the company recently began a U.S.-based trial for a device in this space. This is not expected to occur for some time, however, and Boston Scientific will enjoy a first-to-market advantage, monopolizing this market for a number of years.

Millennium Research Group's Global Markets for Heart Defect Closure Devices 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for congenital heart defect, patent foramen ovale (PFO) and LAA closure devices in the United States, France, Germany, Italy, the United Kingdom and Japan.

For more information: www.MRG.net

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
Abbott Initiates U.S. Pivotal Study of Amplatzer Device for Patent Ductus Arteriosus
News | Congenital Heart| September 05, 2017
Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified...
Overlay Init